Personal information

No personal information available

Activities

Collapse all

Works (8)

Cost-effectiveness of home-based cardiac rehabilitation: a systematic review

Heart
2023-06 | Journal article
DOI: 10.1136/heartjnl-2021-320459
Contributors: Gemma E Shields; Aleix Rowlandson; Garima Dalal; Stuart Nickerson; Holly Cranmer; Lora Capobianco; Patrick Doherty
Source: check_circle
Crossref

An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology

Applied Health Economics and Health Policy
2023-05 | Journal article
DOI: 10.1007/s40258-023-00792-x
Contributors: Holly L. Cranmer; Gemma E. Shields; Ash Bullement
Source: check_circle
Crossref

Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor

AboutOpen
2022-10-24 | Journal article
DOI: 10.33393/ao.2022.2450
Contributors: Roberto Ravasio; Holly Cranmer; Izzie Kearns; Raffaella Viti; Simone Corinti
Source: check_circle
Crossref

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L

Current Medical Research and Opinion
2022-09-02 | Journal article
DOI: 10.1080/03007995.2022.2100653
Contributors: Karen L. Reckamp; Huamao M. Lin; Holly Cranmer; Yanyu Wu; Pingkuan Zhang; Stephen Kay; Laura J. Walton; Junwu Shen; Sanjay Popat; D. Ross Camidge
Source: check_circle
Crossref

Indirect comparisons of brigatinib and alectinib for front-line ALK -positive non-small-cell lung cancer

Future Oncology
2022-06 | Journal article
DOI: 10.2217/fon-2022-0194
Contributors: Karen L Reckamp; Huamao M Lin; Holly Cranmer; Yanyu Wu; Pingkuan Zhang; Laura J Walton; Stephen Kay; Allie Cichewicz; Binod Neupane; Kyle Fahrbach et al.
Source: check_circle
Crossref

Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

Journal of Comparative Effectiveness Research
2022-02 | Journal article
DOI: 10.2217/cer-2021-0201
Contributors: Tanja Podkonjak; Holly Cranmer; Julia Scarisbrick; Grant McCarthy; Cameron Lilley; Lung-I Cheng
Source: check_circle
Crossref

A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology

Journal of Medical Economics
2020-10-02 | Journal article
DOI: 10.1080/13696998.2020.1796360
Contributors: Holly Cranmer; Gemma E. Shields; Ash Bullement
Source: check_circle
Crossref

A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments

Applied Health Economics and Health Policy
2019-12 | Journal article
DOI: 10.1007/s40258-019-00513-3
Contributors: Ash Bullement; Holly L. Cranmer; Gemma E. Shields
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for PharmacoEconomics - open. (1)
How many people are using ORCID?